(Q37815610)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Adjuvant colon cancer chemotherapy: where we are and where we'll go (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Nicola Fazio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Giuseppe Tonini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Evaristo Maiello

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

L Lombardi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

F Morelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S Cinieri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

N Silvestris

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

L Orlando

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

G Colucci

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

36 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

S34-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Adjuvant therapy of colorectal cancer. Why we still don't know

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Systematic review of microsatellite instability and colorectal cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

The paracrine hormone hypothesis of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

The results of colorectal cancer treatment by p53 status: treatment-specific overview

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

P53 abnormalities and outcomes in colorectal cancer: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970018-9

7 January 2021

10.1016/S0305-7372(10)70018-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference